Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease [0.03%]
伴原有间质性肺病的晚期非小细胞肺癌患者二线化疗的现实世界评估
Satoshi Igawa,Masanori Yokoba,Akira Takakura et al.
Satoshi Igawa et al.
Background: The optimal second and subsequent lines of chemotherapy for patients with non-small cell lung cancer (NSCLC) who have preexisting interstitial lung disease (ILD) are unclear. Hence, we examined the clinical ef...
Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication [0.03%]
接受阿特朱单抗治疗的小细胞肺癌患者发生过敏性休克——一个罕见但可能致命的并发症
Yizhuo Zhao,Wei Peng,Muhammad Abbas et al.
Yizhuo Zhao et al.
Immunotherapy has been a revolutionary innovation in cancer therapy in recent years, but it is accompanied by various unique immune-related adverse events (irAEs). Among these irAEs, anaphylactic shock is very rare. Here, we report a case o...
IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer [0.03%]
白细胞介素15活化的淋巴细胞在胃癌过继免疫治疗中的作用研究
Yuefeng Hu,Dong Liu,Peilin Cui et al.
Yuefeng Hu et al.
Objectives To test the antitumor potential of lymphocytes transferred via adoptive cell therapy (ACT) in a mouse model of human gastric cancer (GC), and to evaluate the clinical efficacy and safety of combining lymphocytes as adjuvant thera...
Khaliunsarnai Tsogtbaatar,Diana A Sousa,Debora Ferreira et al.
Khaliunsarnai Tsogtbaatar et al.
Background: Osteosarcoma is a highly malignant bone tumor, most frequently occurring in the rapid bone growth phase. Effective treatment of this disease is hindered by the lack of specific probes for early diagnosis and t...
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition [0.03%]
不可手术的III期非小细胞肺癌患者接受同期和/或序贯免疫检查点抑制联合放化疗的疾病进展预测因素
Julian Taugner,Lukas Käsmann,Monika Karin et al.
Julian Taugner et al.
Background: The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage II...
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors [0.03%]
探究实体瘤中NTRK基因融合的自然史和预后特征
Limin Zhu,Brian Hobbs,Jason Roszik et al.
Limin Zhu et al.
Background: Several TRK inhibitors have demonstrated clinical efficacy in patients with solid tumors harboring NTRK gene fusions. However, the natural history and prognostic implications of NTRK fusions in solid tumors re...
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer [0.03%]
吡格列酮联合塞来昔布治疗非小细胞肺癌抗肿瘤疗效的初步评价研究
Ammu V V V Ravi Kiran,Garikapati Kusuma Kumari,Praveen T Krishnamurthy
Ammu V V V Ravi Kiran
Purpose: Among the lung cancer types, non-small cell lung cancer (NSCLC) is prominent and less responsive to chemotherapy. The current chemotherapeutics for NSCLC are associated with several dose-limiting side effects lik...
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma [0.03%]
一种选择性PI3K抑制剂康帕利西姆单抗联合西妥昔单抗治疗复发和/或转移性头颈部鳞癌的I期临床试验
Grégoire Marret,Nicolas Isambert,Keyvan Rezai et al.
Grégoire Marret et al.
Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. Objective We investigated the dose-limiting toxicities (DLTs), max...
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer [0.03%]
度伐利尤单抗治疗广泛期小细胞肺癌相关的副肿瘤性脊髓炎
Lan Wang,Haiyan Lou,Bo Li et al.
Lan Wang et al.
Paraneoplastic neurologic syndromes(PNSs) caused by immune checkpoint inhibitors(ICIs) is rare and requires clinicians to differentiate between disease progression and immune-related adverse effects(irAEs). We hereby report the case of immu...
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors [0.03%]
聚乙二醇重组人精氨酸酶1（BCT-100）在先进精氨酸营养依赖性肿瘤患者中的安全性、PK/PD及初步抗肿瘤活性研究
Paul N M Cheng,Angela M Liu,Alberto Bessudo et al.
Paul N M Cheng et al.
Background The study determined the safety, pharmacokinetics/pharmacodynamics (PK/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population. Methods This is a Phase I, 3 + 3 dose-escalation, ...